Combination therapy with dutasteride and tamsulosin in men with moderate-to-severe benign prostatic hyperplasia and prostate enlargement: the CombAT (Combination of Avodart® and Tamsulosin) trial rationale and study design

Paul Siami, Claus Roehrborn, Jack Barkin, Ronaldo Damiao, Marek Wyczolkowski, Annette Duggan, Kim Major-Walker, Betsy B. Morrill

Research output: Contribution to journalArticle

61 Citations (Scopus)

Abstract

Benign prostatic hyperplasia (BPH) is a highly prevalent condition in aging men, which can be progressive and lead to acute urinary retention (AUR) and the need for surgery. It is commonly treated with α-blockers and 5α-reductase inhibitors (5ARIs), both of which improve the symptoms of BPH. Long-term treatment with 5ARIs can also reduce the risk of developing AUR and the need for surgery. The landmark Medical Therapy of Prostatic Symptoms (MTOPS) trial demonstrated that over 4 years the combination of the type 2-specific 5ARI, finasteride and the α-blocker doxazosin was more effective than either agent alone in reducing overall clinical progression. Since the initiation of MTOPS, it has been shown that patients with larger prostates and higher prostate-specific antigen (PSA) levels are at greater risk of BPH progression, and are therefore arguably more likely to benefit from combination therapy. The Combination of Avodart and Tamsulosin (CombAT) trial is a 4-year, global, multicenter, randomized, double-blind, parallel-group study designed to investigate the benefits of combination therapy with the dual 5ARI dutasteride and the α-blocker tamsulosin compared with each monotherapy in improving symptoms and long-term outcomes in men with moderate-to-severe symptoms of BPH and prostate enlargement. Symptoms and long-term outcomes (AUR and surgery) will be assessed as separate primary endpoints at 2 and 4 years, respectively. Eligible patients were at least 50 years old with prostate volume ≥ 30 cm3 and PSA level ≥ 1.5 ng/mL. A total of 4838 subjects have been enrolled. This paper describes the rationale, design and baseline data of the CombAT study.

Original languageEnglish (US)
Pages (from-to)770-779
Number of pages10
JournalContemporary Clinical Trials
Volume28
Issue number6
DOIs
StatePublished - Nov 2007

Fingerprint

tamsulosin
Prostatic Hyperplasia
Prostate
Urinary Retention
Prostate-Specific Antigen
Doxazosin
Finasteride
Therapeutics
Oxidoreductases
Dutasteride

Keywords

  • 5-alpha-reductase inhibitors
  • Alpha adrenergic antagonist
  • BPH
  • Clinical trial
  • DHT
  • Prostate
  • Prostate enlargement Combination drug therapy
  • Prostate-specific antigen
  • Prostatic hyperplasia
  • Testosterone

ASJC Scopus subject areas

  • Pharmacology

Cite this

Combination therapy with dutasteride and tamsulosin in men with moderate-to-severe benign prostatic hyperplasia and prostate enlargement : the CombAT (Combination of Avodart® and Tamsulosin) trial rationale and study design. / Siami, Paul; Roehrborn, Claus; Barkin, Jack; Damiao, Ronaldo; Wyczolkowski, Marek; Duggan, Annette; Major-Walker, Kim; Morrill, Betsy B.

In: Contemporary Clinical Trials, Vol. 28, No. 6, 11.2007, p. 770-779.

Research output: Contribution to journalArticle

@article{6c5cc6c91d4b4b919ff965ed8334043b,
title = "Combination therapy with dutasteride and tamsulosin in men with moderate-to-severe benign prostatic hyperplasia and prostate enlargement: the CombAT (Combination of Avodart{\circledR} and Tamsulosin) trial rationale and study design",
abstract = "Benign prostatic hyperplasia (BPH) is a highly prevalent condition in aging men, which can be progressive and lead to acute urinary retention (AUR) and the need for surgery. It is commonly treated with α-blockers and 5α-reductase inhibitors (5ARIs), both of which improve the symptoms of BPH. Long-term treatment with 5ARIs can also reduce the risk of developing AUR and the need for surgery. The landmark Medical Therapy of Prostatic Symptoms (MTOPS) trial demonstrated that over 4 years the combination of the type 2-specific 5ARI, finasteride and the α-blocker doxazosin was more effective than either agent alone in reducing overall clinical progression. Since the initiation of MTOPS, it has been shown that patients with larger prostates and higher prostate-specific antigen (PSA) levels are at greater risk of BPH progression, and are therefore arguably more likely to benefit from combination therapy. The Combination of Avodart and Tamsulosin (CombAT) trial is a 4-year, global, multicenter, randomized, double-blind, parallel-group study designed to investigate the benefits of combination therapy with the dual 5ARI dutasteride and the α-blocker tamsulosin compared with each monotherapy in improving symptoms and long-term outcomes in men with moderate-to-severe symptoms of BPH and prostate enlargement. Symptoms and long-term outcomes (AUR and surgery) will be assessed as separate primary endpoints at 2 and 4 years, respectively. Eligible patients were at least 50 years old with prostate volume ≥ 30 cm3 and PSA level ≥ 1.5 ng/mL. A total of 4838 subjects have been enrolled. This paper describes the rationale, design and baseline data of the CombAT study.",
keywords = "5-alpha-reductase inhibitors, Alpha adrenergic antagonist, BPH, Clinical trial, DHT, Prostate, Prostate enlargement Combination drug therapy, Prostate-specific antigen, Prostatic hyperplasia, Testosterone",
author = "Paul Siami and Claus Roehrborn and Jack Barkin and Ronaldo Damiao and Marek Wyczolkowski and Annette Duggan and Kim Major-Walker and Morrill, {Betsy B.}",
year = "2007",
month = "11",
doi = "10.1016/j.cct.2007.07.008",
language = "English (US)",
volume = "28",
pages = "770--779",
journal = "Contemporary Clinical Trials",
issn = "1551-7144",
publisher = "Elsevier Inc.",
number = "6",

}

TY - JOUR

T1 - Combination therapy with dutasteride and tamsulosin in men with moderate-to-severe benign prostatic hyperplasia and prostate enlargement

T2 - the CombAT (Combination of Avodart® and Tamsulosin) trial rationale and study design

AU - Siami, Paul

AU - Roehrborn, Claus

AU - Barkin, Jack

AU - Damiao, Ronaldo

AU - Wyczolkowski, Marek

AU - Duggan, Annette

AU - Major-Walker, Kim

AU - Morrill, Betsy B.

PY - 2007/11

Y1 - 2007/11

N2 - Benign prostatic hyperplasia (BPH) is a highly prevalent condition in aging men, which can be progressive and lead to acute urinary retention (AUR) and the need for surgery. It is commonly treated with α-blockers and 5α-reductase inhibitors (5ARIs), both of which improve the symptoms of BPH. Long-term treatment with 5ARIs can also reduce the risk of developing AUR and the need for surgery. The landmark Medical Therapy of Prostatic Symptoms (MTOPS) trial demonstrated that over 4 years the combination of the type 2-specific 5ARI, finasteride and the α-blocker doxazosin was more effective than either agent alone in reducing overall clinical progression. Since the initiation of MTOPS, it has been shown that patients with larger prostates and higher prostate-specific antigen (PSA) levels are at greater risk of BPH progression, and are therefore arguably more likely to benefit from combination therapy. The Combination of Avodart and Tamsulosin (CombAT) trial is a 4-year, global, multicenter, randomized, double-blind, parallel-group study designed to investigate the benefits of combination therapy with the dual 5ARI dutasteride and the α-blocker tamsulosin compared with each monotherapy in improving symptoms and long-term outcomes in men with moderate-to-severe symptoms of BPH and prostate enlargement. Symptoms and long-term outcomes (AUR and surgery) will be assessed as separate primary endpoints at 2 and 4 years, respectively. Eligible patients were at least 50 years old with prostate volume ≥ 30 cm3 and PSA level ≥ 1.5 ng/mL. A total of 4838 subjects have been enrolled. This paper describes the rationale, design and baseline data of the CombAT study.

AB - Benign prostatic hyperplasia (BPH) is a highly prevalent condition in aging men, which can be progressive and lead to acute urinary retention (AUR) and the need for surgery. It is commonly treated with α-blockers and 5α-reductase inhibitors (5ARIs), both of which improve the symptoms of BPH. Long-term treatment with 5ARIs can also reduce the risk of developing AUR and the need for surgery. The landmark Medical Therapy of Prostatic Symptoms (MTOPS) trial demonstrated that over 4 years the combination of the type 2-specific 5ARI, finasteride and the α-blocker doxazosin was more effective than either agent alone in reducing overall clinical progression. Since the initiation of MTOPS, it has been shown that patients with larger prostates and higher prostate-specific antigen (PSA) levels are at greater risk of BPH progression, and are therefore arguably more likely to benefit from combination therapy. The Combination of Avodart and Tamsulosin (CombAT) trial is a 4-year, global, multicenter, randomized, double-blind, parallel-group study designed to investigate the benefits of combination therapy with the dual 5ARI dutasteride and the α-blocker tamsulosin compared with each monotherapy in improving symptoms and long-term outcomes in men with moderate-to-severe symptoms of BPH and prostate enlargement. Symptoms and long-term outcomes (AUR and surgery) will be assessed as separate primary endpoints at 2 and 4 years, respectively. Eligible patients were at least 50 years old with prostate volume ≥ 30 cm3 and PSA level ≥ 1.5 ng/mL. A total of 4838 subjects have been enrolled. This paper describes the rationale, design and baseline data of the CombAT study.

KW - 5-alpha-reductase inhibitors

KW - Alpha adrenergic antagonist

KW - BPH

KW - Clinical trial

KW - DHT

KW - Prostate

KW - Prostate enlargement Combination drug therapy

KW - Prostate-specific antigen

KW - Prostatic hyperplasia

KW - Testosterone

UR - http://www.scopus.com/inward/record.url?scp=34848860581&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34848860581&partnerID=8YFLogxK

U2 - 10.1016/j.cct.2007.07.008

DO - 10.1016/j.cct.2007.07.008

M3 - Article

C2 - 17761460

AN - SCOPUS:34848860581

VL - 28

SP - 770

EP - 779

JO - Contemporary Clinical Trials

JF - Contemporary Clinical Trials

SN - 1551-7144

IS - 6

ER -